Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

Barzi Afsaneh; Miksad Rebecca; Surinach Andy; Corvino Frank A.; Wang Siqi; Torres Aracelis Z.; Mamlouk Khalid; Pulgar Sonia; Valderrama Adriana; Bekaii-Saab Tanios; Ahn Daniel

首页> 外文期刊>Pancreas >Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

【24h】

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

机译：在美国脂质体IRINOTECAN方案治疗的转移性胰腺癌患者的现实世界给药模式和结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives

机译：目标

著录项

来源
《Pancreas》 |2020年第2期|共8页
作者
Barzi Afsaneh; Miksad Rebecca; Surinach Andy; Corvino Frank A.; Wang Siqi; Torres Aracelis Z.; Mamlouk Khalid; Pulgar Sonia; Valderrama Adriana; Bekaii-Saab Tanios; Ahn Daniel;
展开▼
作者单位

Univ Southern Calif Norris Comprehens Canc Ctr Los Angeles CA 90007 USA;

Flatiron Hlth New York NY USA;

Genesis Res Hoboken NJ USA;

Genesis Res Hoboken NJ USA;

Genesis Res Hoboken NJ USA;

Flatiron Hlth New York NY USA;

Glean Insights LLC Arlington MA USA;

Ipsen Biopharmaceut Basking Ridge NJ USA;

Ipsen Biopharmaceut Basking Ridge NJ USA;

Mayo Clin Dept Internal Med Div Med Oncol Phoenix AZ USA;

Mayo Clin Dept Internal Med Div Med Oncol Phoenix AZ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
gemcitabine; liposomal irinotecan; metastatic pancreatic cancer; nab-paclitaxel; serum albumin; topoisomerase inhibitor;

机译：吉西他滨;脂质体Irinotecan;转移性胰腺癌;Nab-paclitaxel;血清白蛋白;拓扑异构酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States [J] . Barzi Afsaneh, Miksad Rebecca, Surinach Andy, Pancreas . 2020,第2期

机译：在美国脂质体IRINOTECAN方案治疗的转移性胰腺癌患者的现实世界给药模式和结果
2. ADVERSE EVENTS IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING LIPOSOMAL IRINOTECAN: UNDERSTANDING THE OCCURRENCE AND HOW MANAGEMENT AFFECTS PATIENT OUTCOMES [J] . Jameson Gayle, Caldwell Lana, Mirakhur Beloo, Oncology nursing forum . 2018,第2期

机译：转移性胰腺癌患者接受脂质体IRINOTECAN的不良事件：了解发生以及管理方式如何影响患者结果
3. The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen [J] . Chien-Yu Lu, Hsiang-Lin Tsai, Jaw-Yuan Wang Biomarkers and genomic medicine. . 2013,第3期

机译：UGT1A1基因多态性用于伊立替康剂量调整的FOLFIRI加贝伐单抗一线方案治疗转移性结直肠癌患者的剂量
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan [O] . Jim Koeller, Andy Surinach, Steven R. Arikian, 2020

机译：用脂质体IRINOTECAN治疗的转移性胰腺导管腺癌患者中的真实证据
7. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States [O] . Afsaneh Barzi, Rebecca Miksad, Andy Surinach, 2020

机译：在美国脂质体IRINOTECAN方案治疗的转移性胰腺癌患者的现实世界给药模式和结果

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

摘要

著录项

相似文献

相关主题

期刊订阅